RS-5
Solid Tumors (aggressive, treatment-resistant types)
PreclinicalActive
Key Facts
Indication
Solid Tumors (aggressive, treatment-resistant types)
Phase
Preclinical
Status
Active
Company
About Resolute Science
Resolute Science is a private, preclinical-stage biotech pioneering a new approach to treating solid tumors by targeting tumor-associated macrophages (TAMs) instead of cancer cells directly. Its Macrophage-Targeted Conjugates (MAC-TACs) platform aims to overcome common resistance mechanisms and treat aggressive, late-stage cancers. The lead program, RS-5, has demonstrated consistent anti-tumor efficacy and tolerability across extensive preclinical studies in multiple tumor models. The company is positioned to address a significant unmet need in oncology, particularly for patients who have exhausted conventional treatment options.
View full company profile